15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Arbutus Biopharma Corp, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $5.00 to $5.00, so the covering firms are broadly aligned. The average target of $5.00 sits 3% below the current $5.16. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 1188% this year and -99% next, consensus EPS building from about $-0.03 next quarter toward $-0.11 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Arbutus Biopharma Corp.
As of Sep, 1 of 1 firms rate ABUS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ABUS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.03
Range $-0.03 – $-0.03 · 1 analysts · +104% YoY
Next period, 1 analysts expect Arbutus Biopharma Corp to earn $-0.03 a share (range $-0.03 – $-0.03), versus $-0.01 a year earlier. Full-year consensus is $1.03, growing to $-0.11 the year after.
REVENUE · NEXT QUARTER
$1.4M
Range $1.4M – $1.4M · 1 analysts · +30% YoY
Revenue is expected to reach $1.4M (range $1.4M – $1.4M), +30.0% year-over-year. Full-year consensus is $252.8M, rising to $5.7M next year.
Top analysts covering Arbutus Biopharma Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ABUS.
#1
Keay Nakae
Chardan Capital · Rank #89
Buy
$5.00-3.1% to target
Overall win rate
43%
+ Follow
#2
Ed Arce
HC Wainwright & Co. · Rank #132
Buy
$5.00-3.1% to target
Overall win rate
44%
+ Follow
#3
DD
Dennis Ding
Jefferies
Buy
$7.00+35.7% to target
Coverage
—
+ Follow
ABUS stock forecast FAQ
What is ABUS's average 12-month price target?+
The 1 analysts with a live target average $5.00 for Arbutus Biopharma Corp over the next 12 months, ranging from a $5.00 high to a $5.00 low.
Is ABUS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover ABUS?+
1 analysts have an active rating on Arbutus Biopharma Corp, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering ABUS?+
Among analysts who currently cover ABUS, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #89). Their current call is Buy with a $5.00 target.
What is Arbutus Biopharma Corp's projected EPS for next quarter?+
The consensus estimate is $-0.03 per share (range $-0.03 – $-0.03) across 1 analysts. Full-year EPS is projected at $1.03, rising to $-0.11 the following year.
How much revenue is Arbutus Biopharma Corp expected to report next quarter?+
Consensus revenue is $1.4M (range $1.4M – $1.4M). Full-year revenue is projected at $252.8M, growing to $5.7M next year.
Have analysts been upgrading or downgrading ABUS lately?+
As of Sep, 1 of 1 firms rate ABUS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ABUS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
